TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
UPSC | Exam ScheduleExam Mentor
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | ChinaUnited StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
News Columns | Straight DriveCanada CallingLondon LetterKashmir AngleJammu JournalInside the CapitalHimachal CallingHill View
Don't Miss
Advertisement

EU takes up option to buy 150 million more Moderna Covid-19 vaccines

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

Brussels, June 22

Advertisement

The European Union has decided to take up an option under a supply contract with drugmaker Moderna that allows the bloc to order 150 million additional Covid-19 vaccines produced by the US biotech firm, the EU Commission said on Tuesday.

Advertisement

The announcement comes a week after CureVac, a German biotech firm, said its Covid-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and casting doubt on the potential delivery of hundreds of millions of doses to the EU.

The additional Moderna doses will be delivered next year, the EU executive said in a statement. The shots are part of a contract for 300 million doses, approved in February, of which half has already been ordered by the 27-nation bloc.

The EU has also already ordered another 160 million Moderna shots under an initial supply contract signed in November.

Advertisement

The EU Commission said the second contract with Moderna had also been amended to allow the purchase of vaccines adapted to virus variants as well as jabs for paediatric use and boosters. Reuters

Advertisement
Show comments
Advertisement